Marjolein Y.V. Homs
Erasmus University Rotterdam
Quality of lifeInternal medicineRadiologySurgeryOncologyRandomized controlled trialChemotherapyFOLFIRINOXBrachytherapyCarcinomaEsophagusStentEsophageal cancerPancreatic cancerGemcitabineEsophageal diseaseDysphagiaClinical trialMedicine
63Publications
17H-index
1,813Citations
Publications 68
Newest
In this study, we explored the predictive value of serum microRNA (miRNA) expression for early tumor progression during FOLFIRINOX chemotherapy and its association with overall survival (OS) in patients with pancreatic ductal adenocarcinoma (PDAC). A total of 132 PDAC patients of all disease stages were included in this study, of whom 25% showed progressive disease during FOLFIRINOX according to the RECIST criteria. MiRNA expression was analyzed in serum collected before the start and after one ...
Source
#1Tara M. Mackay (UvA: University of Amsterdam)H-Index: 8
#2Willemieke P.M. Dijksterhuis (UvA: University of Amsterdam)H-Index: 6
Last. Martijn G.H. van Oijen (UvA: University of Amsterdam)H-Index: 38
view all 15 authors...
Abstract null null Background null The impact of pancreatic and periampullary cancer treatment on health-related quality of life (HRQoL) is unclear. null null null Methods null This study merged data from the Netherlands Cancer Registry with EORTC QLQ-C30 and -PAN26 questionnaires at baseline and three-months follow-up of pancreatic and periampullary cancer patients (2015-2018). Propensity score matching (1:3) of group without to group with treatment was performed. Linear mixed model regression ...
Source
#3Anna Dorothea Wagner (CHUV: University Hospital of Lausanne)H-Index: 17
#7B. Groot Koerkamp (EUR: Erasmus University Rotterdam)H-Index: 18
Source
#1Esther N. Pijnappel (UvA: University of Amsterdam)H-Index: 2
#2Willemieke P.M. Dijksterhuis (UvA: University of Amsterdam)H-Index: 6
Last. Hanneke W. M. van Laarhoven (UvA: University of Amsterdam)H-Index: 45
view all 11 authors...
Background null Metastatic pancreatic ductal adenocarcinoma (PDAC) is characterized by a poor survival rate, which can be improved by systemic treatment. Consensus on the most optimal first- and second-line palliative systemic treatment is lacking. The aim of this study was to describe the use of first- and second-line systemic treatment, overall survival (OS), and time to failure (TTF) of first- and second-line treatment in metastatic PDAC in a real-world setting. null Patients and methods null...
Source
#1Fleur van der Sijde (EUR: Erasmus University Rotterdam)H-Index: 4
#2Zakia Azmani (EUR: Erasmus University Rotterdam)H-Index: 1
Last. Quisette P Janssen (EUR: Erasmus University Rotterdam)H-Index: 4
view all 0 authors...
Background:Biomarkers predicting treatment response may be used to stratify pancreatic ductal adenocarcinoma (PDAC) patients for therapy. The aim of this study was to identify circulating tumor DNA...
Source
#1Ingeborg P. M. Griffioen (LUMC: Leiden University Medical Center)H-Index: 1
#2Judith A.C. Rietjens (EUR: Erasmus University Rotterdam)H-Index: 34
Last. Anne M. Stiggelbout (LUMC: Leiden University Medical Center)H-Index: 72
view all 7 authors...
Purpose: Solutions to improve the implementation of shared decision making (SDM) in oncology often focus on the consultation, with limited effects. In this study, we used a service design perspective on the care path of locally advanced pancreatic cancer (LAPC). We aimed to understand how experiences of patients, their significant others, and medical professionals over the entire care path accumulate to support their ability to participate in SDM. Participants and methods: We used qualitative in...
Source
#1Quisette P Janssen (EUR: Erasmus University Rotterdam)H-Index: 4
#2Jacob L. van Dam (EUR: Erasmus University Rotterdam)H-Index: 4
Last. Alice C. Wei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 5
view all 14 authors...
Source
#10Alice C. Wei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 2
BACKGROUND The added value of radiotherapy following neoadjuvant FOLFIRINOX chemotherapy in patients with resectable or borderline resectable pancreatic cancer ((B)RPC) is unclear. The objective of this meta-analysis was to compare outcomes of patients who received neoadjuvant FOLFIRINOX alone or combined with radiotherapy. METHODS A systematic literature search was performed in Embase, Medline (ovidSP), Web of Science, Scopus, Cochrane, and Google Scholar. The primary endpoint was pooled median...
Source
Source
#1Quisette P Janssen (EUR: Erasmus University Rotterdam)H-Index: 4
#2J.L. van Dam (EUR: Erasmus University Rotterdam)H-Index: 1
Last. B. Groot Koerkamp (EUR: Erasmus University Rotterdam)H-Index: 18
view all 21 authors...
BACKGROUND Neoadjuvant therapy has several potential advantages over upfront surgery in patients with localized pancreatic cancer; more patients receive systemic treatment, fewer patients undergo futile surgery, and R0 resection rates are higher, thereby possibly improving overall survival (OS). Two recent randomized trials have suggested benefit of neoadjuvant chemoradiotherapy over upfront surgery, both including single-agent chemotherapy regimens. Potentially, the multi-agent FOLFIRINOX regim...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.